Introduction
Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Recent advancements in precision oncology have transformed treatment outcomes, especially for patients diagnosed with ALK-positive Non-Small Cell Lung Cancer (NSCLC).
LuciAle (Alectinib) Tablets, manufactured by Cordium Pharmaceuticals Pvt Ltd, is an advanced targeted therapy designed to improve survival rates and quality of life for patients with ALK-positive NSCLC.
With increasing global demand for affordable oncology medicines, Cordium Pharmaceuticals is expanding access to high-quality Alectinib treatment across Kenya, Nigeria, Ghana, Philippines, Vietnam, UAE, Saudi Arabia, Uzbekistan, Kazakhstan, USA, UK, and South Africa.
What is LuciAle (Alectinib)?
LuciAle contains Alectinib, a highly selective ALK (Anaplastic Lymphoma Kinase) inhibitor used to treat:
ALK-positive metastatic Non-Small Cell Lung Cancer (NSCLC)
Advanced ALK-positive lung cancer
Lung cancer that has spread to the brain (brain metastases)
Alectinib blocks abnormal ALK proteins that drive cancer growth and spread.
Why is LuciAle (Alectinib) Becoming a Preferred Treatment?
Key Benefits
✅ Highly effective first-line therapy
✅ Strong penetration into the brain to control brain metastases
✅ Delays cancer progression
✅ Improves progression-free survival
✅ Better tolerability compared to older ALK inhibitors
✅ Oral tablet administration for convenient home treatment
How Does Alectinib Work?
Patients with ALK-positive NSCLC have a genetic mutation that causes uncontrolled cancer cell growth.
Alectinib works by:
Blocking ALK signaling pathways
Preventing tumor cell multiplication
Slowing disease progression
Reducing the risk of cancer spreading to the brain
This precision medicine approach targets cancer cells while minimizing damage to healthy cells.
LuciAle (Alectinib) Indications
Doctors may prescribe LuciAle for:
ALK-Positive Metastatic NSCLC
Patients whose tumors test positive for ALK rearrangement.
Brain Metastases Management
Alectinib effectively crosses the blood-brain barrier and helps control cancer spread to the brain.
First-Line Lung Cancer Treatment
Many oncologists now prefer Alectinib as an initial therapy for eligible patients.
LuciAle (Alectinib) Dosage Information
Active Ingredient: Alectinib
Administration: Oral tablets
Typical Adult Dose: As prescribed by an oncologist.
Important: Patients should never adjust dosage without medical supervision.
Possible Side Effects
Like all cancer medicines, LuciAle may cause side effects.
Common side effects include:
Fatigue
Constipation
Muscle pain
Swelling of hands and feet
Liver enzyme elevation
Weight gain
Anemia
Seek immediate medical attention if severe symptoms occur.
Who Should Use LuciAle?
LuciAle may be suitable for:
✔ Adults diagnosed with ALK-positive NSCLC
✔ Patients requiring first-line targeted therapy
✔ Patients with brain metastases
✔ Patients seeking effective long-term disease control
Treatment eligibility should always be confirmed through molecular testing and oncologist evaluation.
Why Choose Cordium Pharmaceuticals Pvt Ltd?
Cordium Pharmaceuticals Pvt Ltd is committed to delivering affordable, high-quality oncology treatments worldwide.
Our Strengths
WHO-GMP quality standards
Global pharmaceutical export expertise
Affordable oncology solutions
Reliable supply chain management
Regulatory documentation support
International distribution network
Global Supply Coverage
Cordium Pharmaceuticals actively serves healthcare providers, hospitals, distributors, and oncology partners in:
Africa
🇰🇪 Kenya
🇳🇬 Nigeria
🇬🇭 Ghana
🇿🇦 South Africa
Asia
🇵🇭 Philippines
🇻🇳 Vietnam
🇺🇿 Uzbekistan
🇰🇿 Kazakhstan
Middle East
🇦🇪 UAE
🇸🇦 Saudi Arabia
Western Markets
🇺🇸 USA
🇬🇧 UK
